Abstract
We have studied the ratio of bioactive to immunoactive (B/I) luteinizing hormone (LH) in eight girls with gonadal dysgenesis before and after estrogen replacement therapy with low doses of oral ethinyl estradiol. The estrogen suppression of bioactive LH, as measured by a rat interstitial cell testosterone assay (RICT), was more profound than the suppression of radioimmuno-assayable (RIA) LH in five girls who had elevated basal serum LH levels: The B/I before therapy was significantly higher (p<0.005) at 2.78±0.12 (n=6) than after three months of 10 μg of ethinyl estradiol (1.44±0.11, n=5), and after three subsequent months of 20 μg of ethinyl estradiol (0.60±0.08, n=3). In two younger patients without elevated basal RIA LH, however, the B/I was low. Estradiol 17-β in concentrations of 0.1, 5 and 10 ng/ml had no effect on testosterone production in the RICT assay.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
